CD206

CD206 분자 정보

영어 이름Macrophage mannose receptor 1시판 약물 수1
임상 약물 수2표적 별명C-type lectin domain family 13 member D,CLEC13D,Macrophage mannose receptor 1-like protein 1,hMR,Macrophage mannose receptor 1,C-type lectin domain family 13 member D-like,CLEC13DL,MRC1L1,MRC1,Mannose Receptor C-Type 1,Mannose Receptor, C Type 1-Like 1,Human Mannose Receptor,MMR,Mannose Receptor, C Type 1,CD206 Antigen,BA541I19.1,CD206
최고 연구 개발 단계Approved
영어 이름Macrophage mannose receptor 1
표적 별명C-type lectin domain family 13 member D,CLEC13D,Macrophage mannose receptor 1-like protein 1,hMR,Macrophage mannose receptor 1,C-type lectin domain family 13 member D-like,CLEC13DL,MRC1L1,MRC1,Mannose Receptor C-Type 1,Mannose Receptor, C Type 1-Like 1,Human Mannose Receptor,MMR,Mannose Receptor, C Type 1,CD206 Antigen,BA541I19.1,CD206
시판 약물 수1
임상 약물 수2
최고 연구 개발 단계Approved

CD206분자 배경

Mrc1 is a conserved checkpoint mediator protein that transduces the replication stress signal to the downstream effector kinase. Mrc1 and its vertebrate homologue Claspin serve as a mediator for replication stress checkpoint signaling, receiving the signal from Mec1/Rad3/ATR sensor kinase and transmitting it to the effector Rad53/Cds1/Chk1 kinase. The loss of mrc1 checkpoint activity results in the aberrant activation of late/dormant origins in the presence of hydroxyurea. Tumor-associated macrophages (TAMs) expressing the multi-ligand endocytic receptor mannose receptor (CD206/MRC1) contribute to tumor immunosuppression, angiogenesis, metastasis, and relapse.

CD206분자 별명

MMR,CD206,hMR,MRC1,CLEC13D,CLEC13DL,MRC1L1

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
68Ga-tilmanoceptPhase 3 ClinicalNavidea Biopharmaceuticals IncAtherosclerosis; Carcinoma, Endometrioid; Endometrial Neoplasms; Tuberculosis
상세
68GaNOTA-Anti-MMR-VHH2Phase 2 ClinicalUniversitair Ziekenhuis BrusselAtherosclerosis; Carcinoma, Non-Small-Cell Lung; Carotid Stenosis; Hodgkin Disease; Lymphohistiocytosis, Hemophagocytic; Lymphoma, Non-Hodgkin; Neoplasms; Sarcoidosis
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
Technetium Tc 99m tilmanoceptNEO3-09ApprovedUniversity Of CaliforniaLymphoseek Kit, Lymphoseek, LymphoaimUnited StatesSolid tumours; Diagnostic agents; Breast Neoplasms; Melanoma; Carcinoma, Squamous Cell; Head and Neck NeoplasmsCardinal Health 414 Llc2013-03-13Anus Neoplasms; Arthritis, Rheumatoid; Breast Neoplasms; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Diagnostic agents; Endometrial Neoplasms; Head and Neck Neoplasms; HIV Infections; Liver Neoplasms; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Rectal Neoplasms; Sarcoidosis; Sarcoma, Kaposi; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms
상세
  • 분자 정보
  • 제품 목록
  • 시판 약물 정보
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호